curasan AG receives license for Osbone®

Kleinostheim, Germany, 10th December 2009 – curasan AG, which is listed in General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received CE certification and, therefore, marketing authorization throughout Europe of the synthetic bone replacement material Osbone®.

Osbone® is suitable for utilisation in general bone surgery, particularly in implantology and oral and maxillofacial surgery associated with jawbone atrophy.
The product consists of an open-celled, porous and biocompatible hydroxylapatite ceramic. It is extremely well tolerated by tissue, is not absorbable and is firmer than standard bone substance, which complies with the wishes of many physicians and dentists. Its spongy, interconnected cells match the natural bone trabecula structure, thereby allow integration into the surrounding viable bone. In contrast to materials with biological origins, Osbone® is not associated with any risks relating to potential infections or the development of allergies.

Hans Dieter Rössler, CEO of curasan AG, explains the advantage of the new product: “Just like the absorbable Cerasorb®, which has already been launched, Osbone® is 100% synthetic and offers practitioners as well as patients the guarantee that the material itself will not result in any adverse effects.“

The market launch is planned for March 2010.


Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button